Co-morbidities in Bronchiectasis

20 Nov 2026 10:20 10:45
Herbert Wang Chun Kwok Speaker Hong Kong
Co-morbidities are highly prevalent in non-cystic fibrosis bronchiectasis and serve as major drivers of disease severity, healthcare utilization, and mortality. While traditional clinical assessments focus primarily on pulmonary architecture, emerging evidence demonstrates that multimorbidity profoundly impacts patient prognosis, necessitating a shift toward comprehensive, multi-organ evaluation. This talk synthesizes current global registry data and international cohorts to examine the prevalence, pathophysiological mechanisms, and prognostic implications of respiratory, systemic, and psychological co-morbidities. Concomitant airway diseases such as COPD and asthma independently predict increased exacerbation frequency, accelerated FEV1 decline, and reduced survival, while chronic rhinosinusitis correlates with altered airway microbiology and type 2 inflammation. Systemic and metabolic complications—including diabetes mellitus, Vitamin D deficiency, and gastroesophageal reflux managed with high-dose proton pump inhibitors—are heavily associated with worse radiological severity, increased hospitalizations, and elevated all-cause mortality. Furthermore, bronchiectasis significantly escalates the risk of cardiovascular events and progressive renal decline, where renal impairment independently triples mortality risk. Dedicated risk stratification tools, such as the Bronchiectasis Aetiology Comorbidity Index (BACI), outperform generic comorbidity indices in predicting long-term survival. Recognizing, screening, and actively managing these extra-pulmonary and overlapping conditions is essential for delivering personalized care and improving long-term patient outcomes.